Actively Recruiting
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-12-16
240
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Recently, the positive results of the Imbrave 150 study (randomized study comparing Atezolizumab+Bevacizumab versus Sorafenib) prompted investigators to redefine their management strategy for advanced HCC by proposing the combination Atezolizumab+ Bevacizumab as first-line treatment in these patients. Identifying new predictive biomarkers of response is essential to optimize the identification of patients who will benefit from immunotherapy. Glypican-3 (GPC-3) is a cell surface glycoprotein that belongs to the family of heparan sulfate chain proteoglycan that is directly implicated in several cancers and more particularly in HCC. GPC-3 overexpression in serum predicts a poor prognosis for patients with HCC and is associated with early tumor recurrence. Through this study, the investigators want to determine whether the concentration of circulating GPC-3 alone, or in combination with other biomarkers used in current practice (PIVKA, AFP) could predict the response to treatment with Atezolizumab/Bevacizumab and OS.
CONDITIONS
Official Title
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to less than 90 years
- Diagnosed with hepatocellular carcinoma (HCC) on cirrhotic liver or chronic liver disease not reaching cirrhosis per TNCD 2021 criteria
- Indication for systemic therapy with Atezolizumab plus Bevacizumab confirmed by multidisciplinary meeting
- Able to understand French
- Informed and agreed to participate in the study
You will not qualify if you...
- HIV infection, known immune deficiency, or immunosuppressive treatment
- Autoimmune diseases or receiving other immunotherapies
- History of portosystemic shunt or liver transplantation
- Presence of sepsis or use of vasoconstrictor drugs
- Pregnant or breastfeeding women
- Individuals under guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Service hépato-gastroentérologie, Hôpital la Pitié-Salpêtrière
Paris, France, 75013
Actively Recruiting
Research Team
M
Manon ALLAIRE, Dr
CONTACT
C
Christine BROCHET, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here